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Mutations of the recombinase-activating genes 1 and 2 (RAG1 and RAG2) in humans 
are associated with a broad range of phenotypes. For patients with severe clinical pre-
sentation, hematopoietic stem cell transplantation (HSCT) represents the only curative 
treatment; however, high rates of graft failure and incomplete immune reconstitution 
have been observed, especially after unconditioned haploidentical transplantation. 
Studies in mice have shown that Rag−/− natural killer (NK) cells have a mature phenotype, 
reduced fitness, and increased cytotoxicity. We aimed to analyze NK cell phenotype and 
function in patients with mutations in RAG and in non-homologous end joining (NHEJ) 
genes. Here, we provide evidence that NK cells from these patients have an immature 
phenotype, with significant expansion of CD56bright CD16−/int CD57− cells, yet increased 
degranulation and high perforin content. Correlation was observed between in  vitro 
recombinase activity of the mutant proteins, NK cell abnormalities, and in vivo clinical 
phenotype. Addition of serotherapy in the conditioning regimen, with the aim of depleting 
the autologous NK cell compartment, may be important to facilitate engraftment and 
immune reconstitution in patients with RAG and NHEJ defects treated by HSCT.
Keywords: natural killer cells, recombinase-activating genes, non-homologous end joining, immunodeficiency, 
cD56, interferon-γ, degranulation
inTrODUcTiOn
Natural killer (NK) cells are effector and immunomodulatory 
cells of the innate immune system. Through recognition of HLA 
class I molecules via activating and inhibitory killer cell immu-
noglobulin-like receptors (KIRs), and upon release of cytolytic 
granules, NK  cells mediate killing of tumor and virus-infected 
cells and editing of dendritic cells, and play an important role 
in graft-versus-leukemia and graft rejection after hematopoietic 
stem cell transplantation (HSCT) (1–4). Furthermore, they 
can modulate immune responses by secreting chemokines and 
cytokines (5, 6).
Human peripheral blood contains two major NK cell subsets 
that can be distinguished based on the density of CD56 and 
CD16 expression on the cell surface: CD56bright CD16−/low and 
CD56dim CD16bright cells. These two NK cell subsets differ for the 
expression pattern of various other cell surface and intracellular 
molecules (7). In particular, CD56bright cells express NKp46, 
CD94/NKG2A, and CCR7 at higher levels than CD56dim NK cells, 
whereas CXCR1 and KIRs are more abundantly expressed by 
CD56dim cells. Furthermore, CD56bright and CD56dim NK cells have 
distinct functional properties, with CD56bright cells being potent 
producers of cytokines, and CD56dim cells being active mediators 
of natural and antibody-dependent cellular cytotoxicity, as also 
reflected by higher intracellular levels of perforin and granzymes 
(8, 9). In healthy adults, CD56bright cells comprise a minority 
(5–10%) of all circulating NK  cells, but because they express 
CCR7, they are attracted to secondary lymphoid organs where 
they represent the predominant NK subset (10, 11). A subset of 
CD56low KIR+ NK  cells, expressing CD57 represent terminally 
differentiated NK cells, whereas a further subset expressing the 
CD56− CD16+ CD57+ KIR+ phenotype are thought to represent 
exhausted NK cells (12).
RAG1 and RAG2 mutations in humans are associated with 
a broad spectrum of clinical and immunological phenotypes, 
including T− B− severe combined immune deficiency (SCID) (13), 
Omenn syndrome (OS) (14), atypical SCID (AS) (15–17), and 
combined immune deficiency with granuloma and/or autoim-
munity (CID-G/A) (18–21). We have previously shown that the 
severity of the clinical and immunological phenotype in patients 
with RAG mutations correlates with the residual recombination 
activity of the mutant recombinase-activating gene (RAG) protein 
3Dobbs et al. NK Cells in RAG Defects
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(22), which may differently affect diversity and composition of 
T and B cell receptor repertoires (23), whereas NK cell differentia-
tion proceeds unaffected. For patients with severe RAG mutations 
presenting with SCID, OS, or AS, HSCT represents the only 
option of definitive cure; however, an increased rate of allograft 
rejection has been observed as compared to patients with other 
forms of SCID (24, 25). An important role of NK lymphocytes in 
mediating rejection of bone marrow allografts has been known 
for decades (26), but why patients with RAG deficiency would 
have a higher risk of graft rejection than other forms of NK+ SCID 
(such as IL7R or CD3 deficiency) remains unknown.
Although RAG genes are not required for NK  cell develop-
ment, data in mice indicate that Rag deficiency affects NK cell 
phenotype and function. It has been shown that expression of 
the RAG genes begins in common lymphoid progenitor cells that 
give rise to T, B, and NK cells (27–29). Studies in mice harbor-
ing transgenic reporters for Rag expression or recombinase 
activity have demonstrated the existence of two populations 
of mature NK  cells: those that have been exposed to transient 
Rag expression during lymphoid differentiation (here termed 
as Ragpast) and NK cells that were not previously exposed to Rag 
(Ragnaive NK  cells) (30). These two populations differ for their 
proliferative capacity and interleukin-2 (IL-2)-mediated Stat5 
phosphorylation, and a progressive decrease in the proportion 
of Ragpast cells has been observed during NK cell differentiation 
(29). Furthermore, Ragnaive NK cells display an activated pheno-
type, increased cytotoxicity, and enhanced apoptosis, thereby 
resulting in poor survival and impaired DNA damage response 
as compared to their Ragpast counterpart (30). It has been postu-
lated that Rag expression in lymphoid progenitors would favor 
selection of cells with optimal levels of expression of proteins 
involved in DNA break repair, including ARTEMIS and DNA 
ligase 4 (LIG4), thereby marking functionally distinct subsets of 
NK cells, and providing Ragpast NK cells with improved survival 
and “fitness.” If confirmed also in humans, the hypothesis that 
RAG deficiency results in the presence of NK cells with a distinc-
tive phenotype and enhanced cytotoxic potential, would provide 
novel mechanistic insights to account for the high rate of primary 
graft failure, incomplete T cell reconstitution, and lack of B cell 
engraftment that are frequently observed following haploidenti-
cal HSCT for RAG deficiency, unless chemotherapy is used (25). 
To test this hypothesis, we have analyzed NK cell phenotype and 
function in a large cohort of patients with mutations in RAG and 
in other genes involved in non-homologous end joining (NHEJ), 
presenting with a variable severity of clinical and immunological 
manifestations, as compared to healthy donors of comparable 
age, and to patients with other forms of T or B cell lymphopenia.
MaTerials anD MeThODs
Patients and controls
The patient population consisted of 66 subjects with molecu-
larly confirmed biallelic mutations in gene involved in V(D)J 
recombination, in particular 35 patients with RAG1, 11 with 
RAG2, 15 with DCLRE1C (ARTEMIS), 3 with LIG4, and 2 with 
NHEJ1 (Cernunnos/XLF) mutations. Based on the clinical 
and immunological phenotype (Table  1), these patients were 
assigned to the following subgroups: T− B− NK+ SCID (n = 19), 
OS (n = 11), AS (n = 13), and delayed onset combined immune 
deficiency (CID, n = 23). For the purposes of analysis, patients 
with OS and with AS, were combined into a single group (OS/
AS, n = 24).
In addition, 22 patients with various other conditions char-
acterized by numerical and/or functional defects of T lympho-
cytes served as a control for T cell deficiency. This group of other 
T cell defects (TCDs) included four patients with CD3G muta-
tions, two patients with Di George syndrome, two patients with 
IL7R deficiency, and one patient each with mutations in MSN, 
JAK3, IL2RG, CD3D, CD3E, RMRP genes, or with MHC class 
II deficiency. In seven cases with T cell deficiency, the underly-
ing diagnosis was unknown, including two infants with severe 
T cell lymphopenia diagnosed at birth with low T cell receptor 
excision circle (TRECs). Based on established criteria (31), 7 of 
these patients met definition of SCID (with <300 T cells/μL), 
and the remaining 15 had either less severe numerical TCDs or 
had functional T cell abnormalities. None of these patients with 
TCD carried mutations in RAG1/2, DCLRE1C, PRKDC, LIG4, 
or NHEJ1 genes.
As a control for B cell lymphopenia, nine patients with molec-
ularly confirmed mutation in the BTK gene, causing X-linked 
agammaglobulinemia (XLA), were also studied.
Finally, 19 healthy infants (age ≤2  years) and 29 healthy 
subjects of >2 years of age served as normal controls for patients 
with SCID and OS/AS, or for patients with CID, respectively.
The study was approved by the Institutional Review Boards of 
Boston Children’s Hospital, the National Institute of Allergy and 
Infectious Diseases (protocols 93-I-0119 and 16-I-N139), and of 
all other referring centers. Blood samples were obtained upon 
written informed consent of the subject or, in the case of minors, 
of their parents or legal guardians. Because of limitations in blood 
volume and/or in the number of cells, not all analyses could be 
performed in each individual included in the study.
analysis of nK cell Phenotype
Peripheral blood was collected in EDTA- or heparin-containing 
vacutainers. Red blood cells were lysed from 200  µl of EDTA-
blood using RBC lysis buffer (eBioscience). Cells were washed 
with FACS buffer (PBS containing 2% FBS), then equally dis-
tributed in five tubes and incubated for 1 h at 4°C with primary 
antibodies (Ab), as described below. After washing with FACS 
buffer, cells were incubated for 30  min at 4°C with secondary 
antibodies, washed again with FACS buffer, and incubated for 
30 min at 4°C with conjugated antibodies. After washing, cells 
were re-suspended in FACS buffer and immediately analyzed 
on LSR Fortessa Flow Cytometer (BD) using FACS Diva v.6.1.3 
software (BD). NK  cells were defined as CD56+ CD3− CD20− 
CD14− cells. Final analysis on the expression of NK cell markers 
was performed using FloJo v.10.2 (TreeStar). The antibodies used 
to define NK cell phenotype were either commercially available 
or were generated in the laboratories of Alessandro Moretta and 
Silvia Parolini.
To analyze the expression of NK  cell surface markers, five 
different tubes were prepared (Table 2), each of which contained 
TaBle 1 | Clinical, molecular, and immunological features of patients with mutations in RAG or non-homologous end-joining (NHEJ) genes.
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cD3 cD4 cD8 cD19 cD16/56
P1 Severe 
combined 
immune 
deficiency 
(SCID)
9 months RAG1: 
p.R332X; 
p.R561H
185 74 24 0 166 883^ <7 <5 <2 Absent neg neg Rotavirus, 
Pseudomonas, 
Enterococcus 
enteritis
No No No
P2 SCID 2 months RAG2: p.I218N; 
p.I218N
25 23 0 1 155 <7 <7 <5 nd nd neg neg PJP No No No
P3 SCID 10 months RAG2: 
p.T125Rfs*10; 
p.T125Rfs*10
230 230 4 0 352 929^ <7 <5 <1 Absent neg neg PJP, 
metapneumovirus, 
oral candidiasis
No No No
P4 SCID 2 months RAG1: 
p.R841Q; 
p.F974L
34 30 4 265 395 371 22 67 38 Markedly reduced neg neg No No No No
P5 SCID 2 weeks RAG1: 
p.R507W; 
p.S966T
286 111 190 16 1,027 235 <15 18 nd Reduced pos nd CMV viremia No No No
P6 SCID 6 months RAG1: 
p.E965X; 
p.E965X
2 2 0 0 252 <7 <7 <5 nd Absent neg neg Klebsiella 
pneumonia
No No No
P7 SCID 2 months RAG1: 
p.M605I/
R561C; 
p.F972S
2 1 0 0 275 325 <7 <5 nd nd pos neg RSV bronchiolitis, 
adenovirus 
pneumonia, CMV
No No No
P8 SCID 6 months RAG2: p.C41W; 
p.C41W
5 1 0 1 804 71 <7 <5 <1 absent neg neg Disseminated BCG No No No
P9 SCID 5 months RAG1: 
p.G720D; 
p.G720D
9 9 0 0 449 766 <7 <5 <1 absent neg neg Cutaneous S. 
aureus abscess
No No No
P10 SCID 5 months RAG1: 
p.C470Lfs*55; 
p.C470Lfs*55
236 90 146 0 80 161 <7 <5 nd nd neg neg No No No No
P11 SCID 1 week RAG1: 
p.C176F; 
p.C176F
23 13 1 573 1,449 754 <7 <5 7.8 Absent neg neg No No No No
P12 SCID 14 months DCLRE1C: 
exon1_3del; 
exon1_3del
11 0 4 10 1,248 722^ 29 16 <1 Absent neg neg Disseminated BCG No AFB + necrotizing 
granulomatous 
lymphadenitis
No
P13 SCID 3 months DCLRE1C: 
exon1_3del; 
exon1_3del
1,076 1,070 10 0 904 50 <7 <5 nd nd neg neg RSV pneumonia No No Yes
P14 SCID 5 months DCLRE1C: 
p.K157Kfs*13; 
p.K157Kfs*13
215 152 61 40 287 540 38 106 nd Markedly 
reduced
neg neg Pseudomonas 
bacteremia, 
recurrent otitis, 
skin abscesses, 
oral candidiasis
No No Papular rash
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cD3 cD4 cD8 cD19 cD16/56
P15 SCID 1 week DCLRE1C: 
exon1_3del; 
exon1_3del
0 0 0 10 840 nd nd nd nd nd nd nd Sepsis No No No
P16 SCID 23 months DCLRE1C: 
p.Y199X; 
p.Y199X
107 50 63 0 498 1,350^ 15 <5 <1 Absent neg neg PJP, RSV 
pneumonia, 
cutaneous 
Pseudomonas 
infection, 
candidiasis
No No No
P17 SCID 28 months DCLRE1C: 
p.Y199X; 
p.Y199X
46 39 7 0 291 1,060 620 nd nd Absent neg neg No No No np
P18 SCID 4 months DCLRE1C: 
p.S32C; IVS11, 
+5g>a
7 1 0 1 598 115 <7 nd nd Absent neg neg Adenovirus 
hepatitis, oral 
ulcers
No No No
P19 SCID 10 months DCLRE1C: 
p.F393fs*8; 
p.F393fs*8
13,997 
(maternal)
9,851 3,221 29 274 830^ <7 nd nd nd pos nd Oral candidiasis No No Generalized 
erythroderma
P20 Omenn 
syndrome 
(OS)
2 months RAG1: 
p.R396H; 
p.R396H
15,760 6,390 9,465 0 1,958 300 <7 <5 1,744 Reduced pos neg Candidiasis, E. 
coli UTI
No No Generalized 
erythroderma
P21 OS 1 month RAG1: 
p.W959X; 
p.W959X
3,424 3,368 0 0 5,003 390 22 16 <2 Absent neg neg Rhinovirus No No Generalized 
erythroderma
P22 OS 2 months RAG1: 
p.R410Q; 
p.M435V
19,230 10,286 8,215 0 816 1,120 <7 101 >5,000 Markedly reduced neg neg Rhinovirus No No Generalized 
erythroderma
P23 OS 2 months RAG1: 
p.R561C; 
p.R716W
4,667 3,976 696 0 7,231 <7 <7 <5 233 Absent neg neg No No No Generalized 
erythroderma
P24 OS 4 months RAG1: 
p.R396C; 
p.R404Q
15,751 8,850 6,957 0 1,389 258 216 <5 2,181 Absent neg neg PJP, rhinovirus No No Generalized 
erythroderma
P25 OS 2 months RAG1: 
p.R561H; 
p.R624H
11,140 6,204 4,931 0 4,564 100 6 302 >5,000 Markedly reduced pos neg No Anti-smooth 
muscle ab
No Generalized 
erythroderma
P26 OS 6 months RAG2: p.G95V; 
p.E480X
2,671 2,351 855 0 36 102 116 235 <5 Markedly reduced neg neg Impetigo, otitis No No Generalized 
erythroderma
P27 OS 1 month RAG1: 
p.R142X; 
p.M458fs*33
5,105 5,029 228 15 4,458 634* 17 8 <2 Markedly reduced pos neg Recurrent URTI/
LRTI
No No Generalized 
erythroderma
P28 OS 1 month RAG1: 
p.S259Afs*5; 
p.S259Afs*5
170 155 15 0 320 815 <7 5 14.4 Markedly 
reduced
neg neg Enterococcus 
faecalis 
bacteremia
Intermittent 
neutropenia
No Generalized 
erythroderma
TaBle 1 | Continued
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cD3 cD4 cD8 cD19 cD16/56
P29 OS 4 months RAG1: 
p.R332X; 
p.L1025fs*39
34,115 22,416 8,364 0 1,338 <7 <7 <5 600 Reduced neg neg Enterovirus 
pneumonia, 
Moraxella 
bacteremia
No No Generalized 
erythroderma
P30 OS 4 months DCLRE1C: 
exon1_3del; 
spling defect 
intron6
26,295 5,085 19,382 0 1,498 120 602 26 192 nd neg neg PJP, rhinovirus No No Generalized 
erythroderma
P31 Atypical SCID 
(AS)
Not known RAG2: 
p.R123C; 
p.R123C
1,056 96 780 23 67 206 11 14 1 nd neg pos Skin abscess, 
recurrent 
pneumonia, 
candidiasis
Lymphadenopathy No No
P32 AS 4 months RAG1: 
p.H375D; 
p.H375D
870 610 210 350 390 370 nd 89 nd Absent nd nd Candidiasis No No Candida rash
P33 AS 17 months RAG1: 
p.R396C; 
p.M435V
360 180 150 31 370 1,036 <7 145 77 Markedly reduced neg neg Vaccine strain 
varicella zoster 
virus (VZV), chronic 
diarrhea
AIHA, vasculitis No Vasculitis
P34 AS 3 years RAG1: 
p.H612R; 
p.A857V
2,063 225 878 612 1,068 2,080 <7 172 1.9 Reduced pos neg Adenovirus 
pneumonia, 
Klebsiella 
pneumonia, 
candidiasis
ANA, TPO Ab No No
P35 AS 2 years RAG1: 
p.F939C; 
p.F939C
729 110 266 41 733 1,260 55 215 78 normal nd nd BCG infection No No No
P36 AS 2 months RAG1: 
p.T173fs*27; 
p.T173fs*27
399 93 209 3 1,205 392 10 <5 113 absent pos neg Pneumonia AIHA No No
P37 AS 16 months RAG2: p.G35A; 
p.G35A
716 277 102 105 209 229 75 327 nd Reduced neg pos Recurrent 
pneumonia 
(Pseudomonas, 
Klebsiella, H. 
influenzae), nail 
candidiasis
AIHA, psoriasis NO Psoriasis
P38 AS 25 months RAG1: 
p.R841W; 
p.R841W
950 220 20 121 665 538^ 146 54 2 Normal neg neg Adenovirus, 
rhinovirus
Tubulointerstitial 
nephritis with 
lymphocytic 
infiltrate
No No
P39 AS 13 months RAG1: 
p.K86Vfs*33; 
p.K86Vfs*33
1,010 80 840 620 460 2,420 194 328 5.6 Markedly reduced pos pos Pseudomonas 
sepsis, CMV, 
BCGitis
Miller-Fisher No No
P40 AS 4 years DCLRE1C: 
p.T65I; p.T65I
558 207 243 36 108 560 19 54 5 nd nd nd HPV No No Warts
TaBle 1 | Continued
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cD3 cD4 cD8 cD19 cD16/56
P41 AS 10 years DCLRE1C: 
p.T65I; p.T65I
683 268 390 24 403 1,190 <7 87 5 nd nd nd HPV, recurrent 
URTI/LRTI
No No Warts
P42 AS 2 years DCLRE1C: 
p.T65I; p.T65I
547 217 268 22 226 240 <7 35 5 Absent nd nd HPV, BCG No No Warts
P43 AS 9 months NHEJ1: 
p.R57X; p.R57X
426 299 98 259 265 600 <7 949 nd Reduced neg neg Adenovirus No No No
P44 CID 6 years RAG2: 
p.T215I; 
p.T215I
840 560 180 70 190 2,480^ <7 170 nd Reduced nd pos Recurrent URTI, 
intermittent 
diarrhea
Neutropenia No No
P45 CID 19 years RAG2: p.G35V; 
p.M322T
457 236 184 165 5,781 <100 <7 <5 nd Reduced neg pos Single episode 
of RTI requiring 
admission at age 
13 years
No Skin 
granulomatosis
Skin 
granulomas
P46 CID 11 years RAG1:p.
R404Q; 
p.R404Q
4,520 3,300 1,220 61 1,004 <200 <7 30 nd Absent pos pos CMV retinitis, 
esophageal 
candidiasis, EBV
Colitis Colon 
granulomatosis
No
P47 CID 8 years RAG1: 
p.H612R; 
p.H612R
526 361 144 373 106 859^ <7 <5 1 Markedly reduced na na Recurrent 
pneumonia, MAC, 
cellulitis 
AIHA No No
P48 CID 17 years RAG1: 
p.K86Vfs*33; 
p.H612R
581 530 80 460 450 390 <7 38 <1 Reduced pos pos Herpes zoster, 
H. influenzae, 
Corynebacterium 
propinquum, 
Pseudomonas
ITP, vitiligo Lung 
granulomatosis
No
P49 CID 11 years RAG1: 
p.L514R; 
p.L514R
2,831 1,658 837 0* 309 <140 <7 130 <18 normal neg pos Recurrent URTI/
LRTI, warts, 
molluscum, 
EBV-LPD
Autoimmune 
cytopenias
Granulomas in 
liver and lungs
Warts, 
molluscum
P50 CID 31 years RAG2: p.F62L; 
p.F62L
380 225 162 78 215 1,000^ <7 25 nd nd na na Disseminated VZV, 
cryptococcus 
meningitis, URTI, 
Pseudomonas 
pneumonia
No Lung 
granulomatosis
P51 CID 12 years RAG1: 
p.R624H; 
p.Y728H
665 406 219 23 177 8 <7 10 <2 Normal neg pos Moderately severe 
VZV, zoster, 
recurrent URTI/LRTI
No No No
P52 CID 9 years RAG2: p.V8I; 
p.D400H
2,253 1,275 774 293 205 910 257 33 29 Normal neg neg S. pneumoniae 
sepsis, severe 
VZV infection, 
recurrent URTI/
LRTI, perianal 
abscess
No No Severe 
atopic 
dermatitis
P53 CID 16 years RAG1: 
p.H612R; 
p.H612R
629 390 141 69 60 637 37 45 nd Normal neg neg Recurrent 
otitris, recurrent 
pneumonia, S. 
aureus skin infection
Alopecia areata, 
AIHA, neutropenia
No No
TaBle 1 | Continued
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cD3 cD4 cD8 cD19 cD16/56
P54 CID 9 years RAG1: 
p.R474C; 
p.L506F
890 500 400 300 130 560 20 60 5 Normal neg pos VZV pneumonia, 
bronchiectasis
No No No
P55 CID 39 years RAG1: 
p.R108X; 
p.W522C
532 336 179 14 166 673 106 69 <1 nd nd nd Pneumonia, warts, 
orolabial HSV, oral 
candidiasis, MRSA 
skin infection
Alopecia, 
autoimmune 
hypothyroidism, 
autoimmune 
hypogonadism
Vocal cord 
granuloma
No
P56 CID 16 years RAG1: 
p.H375D; 
p.Y562C
522 468 18 72 6 1,346^ 420 320 nd Reduced neg neg Pneumonia ITP, neutropenia Granulomatosis 
of skin, liver, 
spleen, lungs
No
P57 CID 10 years RAG1: 
p.R410W; 
p.H375D
273 169 42 56 150 597^ 71 87 nd Normal neg neg Recurrent LRTI Alopecia totalis, 
vitiligo, myasthenia 
gravis
No No
P58 CID 40 years RAG1: 
p.R108X; 
p.W522C
362 235 117 0* 106 976 100 33 0 nd neg neg Recurrent URTI/
LRTI, warts, mouth 
sores, oral and nail 
candidiasis
Alopecia, vitiligo No No
P59 CID 36 years RAG2: 
p.N173S; 
p.E437K
260 204 54 0* 134 1,050^ 17 17 0 Reduced neg pos Septis arthritis, 
recurrent 
pneumonia, warts
Alopecia, myositis No Psoriatic rash
P60 CID 30 months DCLRE1C: 
p.G126D; 
p.L70del
2,800 1,040 2,340 520 510 630^ <7 210 <2 Markedly reduced neg pos Echovirus, 
adenovirus
AIHA no Perianal rash
P61 CID 2 years DCLRE1C: 
p.T65I; p.T65I
540 160 240 16 1,320 135 <7 15 nd nd nd nd Recurrent URTI/
LRTI, aphtous 
stomatitis
Lupus vulgaris No Lupus vulgaris
P62 CID 12 years DCLRE1C: 
p.S147fs*6; 
p.S147fs*6
260 170 90 2 1,635 173 <7 11 2 nd neg neg JC virus-
associated PML
Vasculitis Cutaneous 
granulomatous 
vasculitis
Vasculitis
P63 CID 7 years NHEJ1: 
p.R57G; 
p.R57G
693 319 330 44 195 60 <7 104 nd Reduced neg neg Recurrent URTI/
LRTI
No No No
P64 CID 3 years Ligase 4 (LIG4): 
p.R278H; 
p.R278H
3,088 1,191 1,832 46 2,081 1,400^ <7 167 nd Normal neg pos Chronic calicivirus No No No
P65 CID 8 years LIG4: 
p.K424Rfs*20; 
p.R278H
513 214 289 96 438 622 <7 <10 2 Reduced pos pos Pneumonia, otitis No No No
P66 CID 17 years LIG4: 
p.K449Q; 
p.R814X
771 308 410 12 140 149 <7 <5 <1 Reduced neg neg Recurrent 
URTI/LRTI, 
bronchiectasis, 
skin ringworm 
infection
No No No
^, on immunoglobulin replacement therapy; Ab, antibody; AIHA, autoimmune hemolytic anemia; ANA, anti-nuclear antibodies; BCG, bacillus calmette-guerin; CMV, cytomegalovirus; HPV, human papillomavirus; ITP, immune 
thrombocytopenia; LPD, lymphoproliferative disease; LRTI, lower respiratory tract infection; PJP, Pneumocystis jiroveci pneumonia; RSV, respiratory syncitial virus; TPO, thyroid peroxidase; URTI, upper respiratory tract infection; 
UTI, urinary tract infection; VZV, Varicella zoster virus.
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TaBle 2 | Combination of antibodies used to characterize natural killer cell 
phenotype.
Tube # antibody source
1 IgG1 isotype control Biolegend
IgG2a isotype control Biolegend
IgG2b isotype control Biolegend
PE-conjugated goat anti-mouse IgG1 Southern Biotech
PE-conjugated goat anti-mouse IgG2a Southern Biotech
PE/Cy7-conjugated goat anti-mouse IgG2b Southern Biotech
FITC-conjugated anti-CD3 Beckman Coulter
PC5-conjugated anti-CD56 Beckman Coulter
FITC-conjugated anti-CD14 Beckman Coulter
FITC-conjugated anti-CD20 Biolegend
APC/Cy7-conjugated IgG1 Biolegend
BV510-conjugated IgG1 Biolegend
BV421-conjugated mouse IgM Becton-Dickinson
2 Anti-NKG2A (Z199) [IgG2b] A. Moretta, S. Parolini
Anti-KIR2 DL1/S1 (AZ115) [IgG1] A. Moretta, S. Parolini
Anti-KIR2 DL2/S2 (GL183) [IgG1] A. Moretta, S. Parolini
Anti-KIR3D (AZ158) [IgG2a] A. Moretta, S. Parolini
PE-conjugated goat-anti-mouse IgG1 Southern Biotech
PE-conjugated goat anti-mouse IgG2a Southern Biotech
PE/Cy7-conjugated goat anti-mouse IgG2b Southern Biotech
FITC-conjugated anti-CD3 Beckman Coulter
PC5-conjugated anti-CD56 Beckman Coulter
FITC-conjugated anti-CD14 Beckman Coulter
FITC-conjugated anti-CD20 Biolegend
APC/Cy7-conjugated anti-CD16 Biolegend
BV510-conjugated anti-CD69 Biolegend
BV421-conjugated anti-CD57 Becton-Dickinson
3 Anti-SIGLEC7 (Z176) [IgG2b] A. Moretta, S. Parolini
Anti-LIR1 (F278) [IgG1] A. Moretta, S. Parolini
PE-conjugated goat-anti-mouse IgG1 Southern Biotech
PE/Cy7-conjugated goat anti-mouse IgG2b Southern Biotech
FITC-conjugated anti-CD3 Beckman Coulter
PC5-conjugated anti-CD56 Beckman Coulter
FITC-conjugated anti-CD14 Beckman Coulter
FITC-conjugated anti-CD20 Biolegend
APC/Cy7-conjugated anti-CD16 Biolegend
BV510-conjugated anti-CD69 Biolegend
BV421-conjugated anti-CD57 Becton-Dickinson
4 Anti-NKG2C [IgG2b] R&D Systems
Anti-KIR2 DL1/S1 (11PB6) [IgG1] A. Moretta, S. Parolini
Anti-KIR2 DL2/S2 (GL183) [IgG1] A. Moretta, S. Parolini
Anti-KIR3D (AZ158) [IgG2a] A. Moretta, S. Parolini
PE-conjugated goat-anti-mouse IgG1 Southern Biotech
PE-conjugated goat anti-mouse IgG2a Southern Biotech
PE/Cy7-conjugated goat anti-mouse IgG2b Southern Biotech
FITC-conjugated anti-CD3 Beckman Coulter
PC5-conjugated anti-CD56 Beckman Coulter
FITC-conjugated anti-CD14 Beckman Coulter
FITC-conjugated anti-CD20 Biolegend
APC/Cy7-conjugated anti-CD16 Biolegend
BV510-conjugated anti-CD69 Biolegend
BV421-conjugated anti-CD57 Becton-Dickinson
5 Anti-CXCR1 [IgG1] Santa Cruz
PE-conjugated goat-anti-mouse IgG1 Southern Biotech
FITC-conjugated anti-CD3 Beckman Coulter
PC5-conjugated anti-CD56 Beckman Coulter
FITC-conjugated anti-CD14 Beckman Coulter
FITC-conjugated anti-CD20 Biolegend
APC/Cy7-conjugated anti-CD16 Biolegend
Pacific Blue-conjugated anti-CCR7 Biolegend
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FITC-conjugated antibodies directed against CD3, CD20, and 
CD14, to gate out T cells, B cells, and monocytes. Furthermore, 
tube #1 contained isotype controls, whereas tubes #2–5 contained 
antibodies to NK cell markers.
analysis of Perforin expression
Intracellular content of perforin was analyzed in a limited 
number of patients with SCID/OS/AS due to RAG/NHEJ 
defects and in healthy infants. Briefly, PBMCs were first stained 
with a mixture of FITC-conjugated mAbs directed against 
CD3, CD20, and CD14, as well as with PC5-labeled anti-CD56 
mAb, and incubated for 30  min at 4°C. After treatment with 
200  µl of Cytofix/Cytoperm (BD-Bioscience, Pharmigen CA, 
USA) for 20 min at 4°C, cells were washed with 1 ml of saponin 
(0.1% solution in PBS), and then stained with 5 µl of purified 
R-PE-labeled anti-perforin mAb (Ancell). After washing, the 
proportion of CD3− CD14− CD20− CD56+ cells expressing 
perforin and the mean fluorescent intensity (MFI) of perforin 
were immediately analyzed on LSR Fortessa Flow Cytometer 
(BD) using FACSDiva software (BD). Final analysis was done 
using FloJo v.10.2 (TreeStar).
analysis of nK cell Degranulation
Natural killer cell degranulation activity was tested against the 
K562 erythroleukemia human cell line. In particular, PBMCs 
derived from patients and from healthy donors were obtained 
upon Ficoll separation of heparinized blood samples, and incu-
bated with or without 100 U/mL recombinant human IL-2 (NIH) 
at 37°C overnight. Cells were then incubated with target cells at 
an effector:target ratio of 1:3 in a final volume of 200 µl in round-
bottomed 96-well plates at 37°C and 5% CO2 for 4 h in culture 
medium supplemented with anti-CD107a-PE (BD Biosciences 
Pharmingen, San Diego, CA, USA) monoclonal antibody. Cells 
were then surface-stained with FITC anti-CD3, PC5 anti-CD56, 
FITC anti-CD14 (Beckman Coulter), FITC anti-CD20, and APC/
Cy7 anti-CD16 (BD Biosciences Pharmingen, San Diego, CA, 
USA) Ab for 30 min at 4°C. The cells were washed, and the pro-
portion of CD3− CD14− CD20− CD56+ cells expressing CD107a 
was analyzed immediately on LSR Fortessa Flow Cytometer (BD) 
using FACSDiva v6.1.3 software (BD Biosciences, Mountain 
View, CA, USA). Final analysis was performed using FloJo v.10.2 
(TreeStar). The threshold to define CD107a expression in cells co-
cultured with K562 target cells (in the presence or absence of IL-2) 
was set up on cells cultured with IL-2 alone, without K562 cells.
analysis of interferon-γ (iFn-γ) Production
To detect intracellular production of IFN-γ, PBMCs from patients 
and healthy donors were incubated overnight at 37°C with IL-12 
(0.5 ng/ml), or IL-12 (0.5 ng/ml) and IL-18 (0.1 ng/ml) combined. 
Surface staining was done by incubating the cells with FITC anti-
CD3, PC5 anti-CD56, FITC anti-CD14 (Beckman Coulter), FITC 
anti-CD20, and APC/Cy7 anti-CD16 (BD) mAbs for 30 min at 
4°C. Cells were then washed, fixed, and permeabilized with BD 
Cytofix/Cytoperm kit (BD Biosciences Pharmingen). IFN-γ pro-
duction was detected by subsequent intracellular staining with 
PE-conjugated anti-IFN-γ (BD Biosciences Pharmingen). After 
FigUre 1 | Absolute count of T (a), B (B), and natural killer (NK) (c) 
lymphocytes at the time of evaluation of NK cell phenotype and function. The 
area shown in shaded gray represents normal values for age. Different 
symbols (circle, square, diamond) are used to indicate patients with severe 
combined immune deficiency (SCID), Omenn syndrome/atypical SCID (OS/
AS), and delayed onset combined immune deficiency (CID), respectively. 
Open circles identify patients with mutations of the recombinase-activating 
gene (RAG), and close symbols identify patients with mutations in genes 
involved in non-homologous end joining (NHEJ).
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washing, the proportion of CD3− CD14− CD20− CD56+ cells 
expressing IFN-γ was immediately analyzed on LSR Fortessa 
Flow Cytometer (BD) using FACSDiva software (BD). Final 
analysis was done using FloJo v.10.2 (TreeStar).
statistical analysis
Statistical analysis of the in vitro recombination activity of mutant 
RAG and ARTEMIS proteins, and of the expression of NK cell 
markers in patients and controls was performed using Mann–
Whitney test for non-parametric variables.
resUlTs
Demographic and clinical Features
At the time of evaluation, mean age (±SEM) was significantly 
lower in patients with SCID (7.1 ±  1.72  months; range: 0.25–
28 months) and in those with OS/AS (15.96 ± 5.41 months; range: 
24–480 months) than in patients with CID (177.2 ± 28.22 months; 
range: 24–480 months; p < 0.0001).
A clinical history of significant infections was present in 
60 patients with RAG/NHEJ gene defects (Table  1). Candida 
(n =  11), Pseudomonas (n =  7), human papillomavirus (HPV, 
n = 7), adenovirus (n = 6), varicella zoster virus (VZV, n = 6), 
Pneumocystis jiroveci (n =  5), Bacillus Calmette-Guerin (BCG, 
n = 5), and rhinovirus (n = 5) were the most common patho-
gens. In particular, P. jiroveci pneumonia was observed only in 
patients with SCID or OS/AS, whereas severe VZV infection was 
mostly restricted to patients with CID. Cytomegalovirus (CMV) 
and Epstein–Barr virus (EBV) infections were documented in 
13 patients each, but were clinically significant only in 4 and 
3 patients, respectively. Two SCID patients (P4 and P11) were 
diagnosed at birth following newborn screening, and infec-
tions were effectively prevented with isolation and prophylactic 
antimicrobials.
Autoimmunity and/or autoantibody production were docu-
mented in 23 patients, and were more common in patients present-
ing with CID (14 out of 21 patients) than in those with SCID 
(0/19) or with OS/AS (9/24). Cytopenias were the most frequent 
manifestation of autoimmunity and were documented in 11 patients 
(4 with OS/AS and 7 with CID). Alopecia and/or vitiligo were 
observed in six CID patients. Granulomatous disease was present 
in eight patients with CID. Finally, 12 patients (P20–P31) had typi-
cal features of OS (generalized erythroderma, lymphadenopathy, 
hepatosplenomegaly).
immunological Phenotype
The count of circulating CD3+, CD19+, and CD3− CD56+ cells in 
patients belonging to the various groups (SCID, OS/AS, and CID) 
is shown in Figure  1. With the exception of one SCID patient 
(P19) who had a high count of maternal T cells (13997 cells/μl), 
all others had severe T cell lymphopenia (Figure 1A). By contrast, 
a higher count of autologous T cells was recorded in patients with 
CID and especially in patients with OS/AS. B cell lymphopenia 
was observed in the vast majority of patients, irrespective of the 
clinical phenotype (Figure 1B). By contrast, NK cell count was 
either normal or increased in most patients (Figure 1C).
Data on in vitro proliferation to phytohemagglutinin (PHA) 
were available in 51 patients. Response was absent (<10% of 
lower limit of normal, LLN) in 17, markedly reduced (10–30% 
of LLN) in 11, reduced (>30% of LLN, but lower than LLN) in 
14, and normal in 9 patients. T cell proliferation to PHA was bet-
ter preserved in patients with CID; among 18 such patients for 
whom information was available, 15 had either normal (n = 7) or 
reduced (n = 8) response.
Low serum levels of IgA and IgM were detected in the major-
ity of SCID patients (Table  1); serum IgG in this group was 
less informative because of the presence of maternally derived 
immunoglobulins. Immunoglobulin levels were more variable in 
patients with OS/AS and in those with CID. In particular, among 
23 CID patients, 17 had either low serum IgG (n = 9) or were 
under immunoglobulin replacement therapy (n = 8) and 15 had 
undetectable serum IgA.
FigUre 2 | Graphical representation of the recombination activity 
(mean ± SD) of RAG and DCLRE1C mutant alleles in patients with severe 
combined immune deficiency (SCID), Omenn syndrome/atypical SCID (OS/
AS), and delayed onset combined immune deficiency (CID). *p < 0.05; 
***p < 0.005; ****p < 0.001.
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correlation between clinical Phenotype 
and recombination activity sustained by 
the Mutant alleles
Molecular analysis of the patients included in this study identi-
fied a total of 41 RAG1, 16 RAG2, 11 DCLRE1C, 4 LIG4, and 2 
NHEJ distinct gene mutations (Table 1). Using a flow cytometry-
based assay, we have previously reported correlation between 
recombination activity supported by RAG and DCLRE1C mutant 
alleles and the clinical and immunological disease phenotype 
(22, 32). For the patient cohort included in this study, data on 
in  vitro recombination activity were available for 36 RAG1, 9 
RAG2, and 6 DCLRE1C mutant alleles. Upon plotting for each 
patient the recombination activity associated with each of the 
two mutant alleles, a significant genotype–phenotype correlation 
was observed, with higher residual recombination activity for 
mutant alleles associated with a CID phenotype than for those 
associated with OS/AS or SCID (Figure 2).
circulating nK cells from healthy infants 
comprise a high Proportion of cD56bright 
cells
According to a widely accepted scheme, human NK cell differ-
entiation is marked by changes in the expression of cell surface 
and intracytoplamsic markers, so that five distinct stages of 
NK  cell development are recognized (33). In peripheral blood 
from healthy controls, both stage 4 (CD56bright CD16−) and stage 
5 (CD56+ CD16hi) NK cells are detectable. In particular, in nor-
mal adults, CD56bright CD16− cells account for only 5–10% of all 
circulating NK cells. By contrast, a higher percentage of CD56bright 
cells was detected in healthy infants (Figures 3A,B). Moreover, 
the proportion of CD16+ cells was lower in infants than in healthy 
controls greater than 2  years of age (Figures  3A,C). Finally, 
NK  cells from healthy infants included a lower proportion of 
cells expressing CD57 (Figures  3A,D), KIRs (Figures  3A,E), 
and CXCR1 (Figures 3A,F), whereas the percentage of NK cells 
expressing NKG2A was higher in infants than in older healthy 
controls (Figures 3A,G).
Markedly increased Proportion of 
cD56bright nK cells in the Peripheral Blood 
of Patients with rag and nheJ Defects 
correlates with the clinical Phenotype
A recent study in Rag−/− mice has unexpectedly disclosed abnor-
malities of NK phenotype and function, with increased propor-
tion of mature, activated cells with increased cytotoxic activity 
and reduced survival (30). In order to assess whether similar 
abnormalities exist in patients with RAG or NHEJ defects, and 
to establish whether such abnormalities, if present, correlate with 
the severity of the clinical phenotype and with residual function 
of the mutant protein, we have analyzed the expression of CD56 
and CD16 on the surface of CD3− CD14− CD20− peripheral blood 
NK cells from patients and controls. As shown in Figures 4A,B, 
patients with SCID due to RAG/NHEJ defects had a high pro-
portion of CD56bright CD16− NK cells (mean ± SEM: 34.7 ± 4.4), 
that exceeded what was observed in healthy infants (13.9 ± 3.3; 
p  =  0.0007). Similarly, the proportion of CD56bright CD16− 
NK cells was higher in patients with CID than in healthy controls 
greater than 2 years of age (10.4 ± 1.8 vs. 5.1 ± 0.7; p = 0.0431; 
Figures 4A,B). Among infants with RAG/NHEJ defects, the pro-
portion of CD56bright CD16− NK cells was higher in those present-
ing with SCID than in those with OS/AS (p = 0.0008; Figure 4B). 
In order to investigate whether the increase in the proportion of 
CD56bright NK cells was secondary to numerical and/or functional 
abnormalities of T and/or B cells, we also analyzed a group of 
patients with other forms of TCD or with XLA. The proportion 
of CD56bright CD16− NK cells in these groups was similar to that 
of healthy controls, and significantly lower than in patients with 
SCID due to RAGH/NHEJ defects (Figure 4B). Among patients 
with TCD, no correlation was observed among the proportion of 
CD56bright NK cells and the severity of T cell lymphopenia, indi-
cating that the increase of CD56bright NK cells observed in SCID 
patients with RAG/NHEJ defects is not simply secondary to T cell 
lymphopenia. Furthermore, the proportion of CD56bright CD16int 
NK cells, that are considered to represent an intermediate step 
of differentiation between CD56bright CD16− and CD56dim CD16hi 
cells, was significantly higher in infants with SCID due to RAG/
NHEJ defects than in healthy infants, patients with TCD or with 
XLA (p < 0.0001; Figure 4C). A higher percentage of CD56bright 
CD16int NK cells was also observed in patients with CID than in 
healthy controls greater than 2 years of age (p < 0.05; Figure 4C). 
Finally, patients with SCID due to RAG/NHEJ defects had a lower 
proportion of CD56dim CD16hi NK cells when compared to healthy 
infants (p =  0.0007; Figure  4D). Similar results were obtained 
when comparing patients with CID versus healthy controls older 
than 2 years of age (p = 0.0011).
cD56bright nK cells from infants with rag/
nheJ Defects have an immature 
Phenotype
The data reported above on CD56 and CD16 surface expres-
sion indicate that patients with RAG/NHEJ defects have an 
FigUre 3 | Flow cytometry analysis of natural killer cell phenotype in healthy infants (<2 years of age) and healthy donors >2 years of age. (a) Representative 
analysis of the expression of CD56, CD16, CD57, killer cell immunoglobulin-like receptors (KIRs), CXCR1, and NKG2A in a healthy infant and a healthy donor 
>2 years of age; (B–g) percentage of CD56bright (B), CD16+ (c), CD57+ (D), KIR+ (e), CXCR1+ (F), and NKG2A+ (g) cells upon gating on CD3− CD19− CD14− 
CD56+ cells. For NKG2A, different gates are shown to indicate NKG2A+, NKG2A++, and NKG2A+++ cells. For each marker, positivity was defined as fluorescence 
intensity above that of isotype control. Bars represent mean ± SD values. **p < 0.01; ****p < 0.001.
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abnormal distribution of NK  cell subsets, with an increased 
proportion of more immature cells as compared to what is 
observed in healthy controls. In order to further confirm this, 
we analyzed the expression of additional surface markers that 
are differentially expressed in CD56bright versus more mature 
CD56dim NK cells. As compared to healthy controls >2 years of 
age, patients with CID had a lower proportion of CD57+ NK cells 
(p =  0.0022; Figures  5A,B). Furthermore, patients with SCID 
FigUre 4 | Flow cytometry analysis of CD56 and CD16 expression in natural killer cells from patients and controls. (a) Representative analysis of the expression of 
CD56 and CD16 in CD3− CD19− CD14− CD56+ cells from one patient each belonging to the severe combined immune deficiency (SCID), Omenn syndrome (OS), 
delayed-onset combined immune deficiency (CID), other forms of T cell defect (TCD), and X-linked agammaglobulinemia (XLA), respectively. (B–D) Percentage of 
CD56bright CD16− (B), CD56bright CD16int (c), and CD56dim CD16hi (D) cells among CD3− CD19− CD14− CD56+ cells. For each marker, positivity was defined as 
fluorescence intensity above that of isotype control. Bars represent mean ± SD values. *p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001.
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had fewer CD57+ NK  cells than patients with other forms of 
TCD (p = 0.0041), and a similar trend was also observed when 
compared to infant controls, although the difference did not 
reach statistical significance (Figure 5B).
In normal subjects, circulating stage 4 CD56bright NK  cells 
are characterized by high levels of expression of NKG2A and 
of the chemokine receptor CCR7, which facilitates homing to 
lymphoid tissues. By contrast, expression of KIRs and of the 
chemokine receptor CXCR1 is virtually absent in CD56bright 
NK  cells. As compared to healthy controls, the proportion 
of NK  cells expressing NKG2A at high density was increased 
in patients with SCID and CID due to RAG/NHEJ defects 
(Figures  5C,D), and by contrast, the percentage of CXCR1+ 
NK  cells was reduced (Figures  5E,F). Furthermore, patients 
with SCID due to RAG/NHEJ defects had a lower proportion of 
NK cells expressing KIR than healthy infants, patients with OS 
and those with other forms of TCD (Figures 5G,H). While the 
proportion of CCR7+ cells was higher in healthy infants than 
in healthy controls >2  years of age (Figure  6), no significant 
differences were observed in the percentage of CCR7+ NK cells 
between patients with RAG/NHEJ defects and healthy controls. 
Notably, CCR7 expression was downregulated during the 
transition from CD56bright CD16− to CD56bright CD16int cells 
(data not shown). Furthermore, the proportion of NK  cells 
expressing Siglec-7, leukocyte Ig-like receptor (LIR)-1, or the 
activation marker CD69 was similar in patients and healthy 
controls, although interestingly a high proportion of Siglec-7+ 
NK  cells were detected in the control group of patients with 
XLA (Figure  6). Overall, these data support the notion that 
the CD56bright NK cells that are more abundant in patients with 
RAG/NHEJ defects represent immature NK  cells and provide 
evidence for a genotype–phenotype correlation in this group of 
diseases.
impact of Viral infections on nK cell 
Phenotype
Recombinase-activating gene and NHEJ defects lead to 
increased susceptibility to viral infections, including CMV, EBV, 
and VZV. It has been reported that viral infections (and CMV in 
particular) may lead to significant changes of NK cell phenotype 
and function, with accumulation of cytotoxic CD56dim NKG2C+ 
NKG2A− KIR+ CD57+ cells (34). Expansion of these cells does 
FigUre 5 | Flow cytometry analysis of the expression of CD57 (a,B), NKG2A (c,D), and CXCR1 (e,F), and killer cell immunoglobulin-like receptors (KIRs) (g,h) 
among CD3− CD19− CD14− CD56+ cells. In panels (a,c,e,g), representative examples are shown for one patient each belonging to the severe combined immune 
deficiency (SCID), Omenn syndrome (OS), and delayed-onset combined immune deficiency (CID) subgroups. For each marker, positivity was defined as 
fluorescence intensity above that of isotype control. Bars represent mean ± SD values. *p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001.
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not require T cells, as shown in an IL7R-deficient SCID infant 
after CMV infection (35). A significant proportion (26/66, 
39.4%) of the patients with RAG/NHEJ defects included in this 
study had a documented history of CMV, EBV, VZV or severe 
JC virus (JCV) infection (Table 1). The proportion of NK cells 
expressing NKG2C was not statistically different in patients with 
FigUre 7 | (a) Percentage of NKG2C+ cells among CD3− CD19− CD14− CD56+ cells from patients and controls. (B) Percentage of NKG2C+ cells among natural 
killer (NK) cells from patients with recombinase-activating gene (RAG)/non-homologous end-joining (NHEJ) defects with positive (+) or negative (−) history of 
infections due to cytomegalovirus (CMV), Epstein–Barr virus (EBV), varicella zoster virus (VZV), or JC virus (JCV). (c) Percentage of NKG2C+ cells among NK cells 
from patients with RAG/NHEJ defects presenting with severe combined immune deficiency (SCID), Omenn syndrome/atypical SCID (SCID/OS/AS), or with delayed 
onset combined immune deficiency (CID), and divided into two groups according to the presence (+) or absence (−) of a history of CMV infection. (D) Percentage of 
CD56dim CD16+ cells among NK cells from patients with RAG/NHEJ defects presenting with SCID/OS/AS or with CID, and with either positive (+) or negative (−) 
history of CMV infection. (e) Percentage of CD56− CD16+ CD57+ cells among CD3− CD14− CD20− peripheral blood mononuclear cells. Bars represent mean ± SD 
values. *p < 0.05; **p < 0.01; ***p < 0.005.
FigUre 6 | Percentage of CD3− CD19− CD14− CD56+ cells expressing CCR7 (left panel), Siglec-7 (middle panel), or CD69 (right panel) in patients and controls. For 
each marker, positivity was defined as fluorescence intensity above that of isotype control. Bars represent mean ± SD values. *p < 0.05; **p < 0.01; ***p < 0.005; 
****p < 0.001.
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SCID, OS/AS, or CID versus healthy controls (Figure  7A). 
Furthermore, when patients were divided into two groups 
according to their history of CMV, EBV, VZV, or severe JCV 
infection, no differences were observed in the proportion of 
NKG2C+ NK cells (Figure 7B). Even when patients with SCID/
OS/AS or with CID were divided into two subgroups based on 
their CMV infection history, no difference was observed in the 
proportion of NKG2C+ (Figure 7C) and of CD56dim (Figure 7D) 
FigUre 8 | Percentage of interferon-γ (IFN-γ) expressing cells among 
CD56bright and CD56dim natural killer cells from patients and controls, upon 
in vitro stimulation with IL-12 and IL-18. Bars represent mean ± SD values. 
*p < 0.05; ***p < 0.005; ****p < 0.001.
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NK cells. Finally, although a higher percentage of “exhausted” 
NK cells with a CD56− CD16+ CD57+ phenotype was detected 
in patients with SCID, OS/AS, and TCD than in healthy infants 
(Figure 7E), no correlation was observed with a history of viral 
infections.
cD56bright cells from Patients with rag/
nheJ Defects are Potent Producers  
of iFn-γ
Circulating CD56bright NK  cells serve an immunoregulatory 
function through secretion of various cytokines (IFN-γ, TNF-α, 
IL-10) (36). In order to assess this aspect of NK  cell function, 
we performed in  vitro stimulation with IL-12 and IL-18, and 
analyzed intracellular expression of IFN-γ upon gating separately 
on CD56bright vs. CD56dim NK cells. As expected, in both patients 
and controls CD56bright cells were more potent producers of IFN-γ 
than CD56dim cells, but both subsets were capable of producing 
this cytokine (Figure 8). However, CD56dim cells from patients 
with SCID and with OS/AS due to RAG/NHEJ defects showed 
impaired IFN-γ production when compared to equivalent cells 
from healthy infants or patients with TCD. A similar trend was 
observed in patients with CID versus healthy controls greater 
than 2 years of age (Figure 8).
nK cells from Patients with sciD due to 
rag/nheJ Defects have increased 
Degranulation capacity in the absence  
of il-2-Mediated stimulation, and express 
a higher amount of intracellular Perforin 
than nK cells from healthy infant controls
Previous data had shown that NK  cells from rag−/− mice have 
increased cytotoxic activity (30). To investigate the cytolytic 
machinery of NK cells, we have analyzed NK cell degranulation 
in response to K562 target cells, in the absence or presence of 
IL-2. It is well known that human CD56bright NK cells have reduced 
cytotoxic activity when compared to CD56dim cells (8). In spite 
of the markedly increased proportion of CD56bright NK cells, we 
observed that in the absence of stimulation with IL-2, NK cells 
from patients with SCID due to RAG/NHEJ defects have 
increased degranulation capacity when compared to NK  cells 
from healthy infants (Figure 9A, left panel). In particular, CD56dim 
NK cells from patients with SCID showed increased degranula-
tion when compared to the equivalent subset of NK cells from 
healthy infants (Figure 9A, middle panel). A similar trend was 
observed also for CD56bright NK cells, but the difference between 
SCID patients and controls did not reach statistical significance 
(Figure  9A, middle panel). Stimulation with IL-2 significantly 
increased NK  cell degranulation capacity to similar levels in 
patients and controls (Figure  9A, right panel). Although the 
amount of intracellular perforin could be measured only in 
a small number of patients with SCID, a significantly higher 
mean fluorescent intensity (MFI) was observed in unstimulated 
NK cells from patients than from healthy infants (Figure 9B).
DiscUssiOn
In this manuscript, we have demonstrated that NK  cells from 
healthy infants comprise a higher proportion of CD56bright CD16−/int 
CD57− cells than what is observed in older healthy subjects, con-
firming previous observations (37–39). Several lines of evidence 
indicate that CD56bright cells represent precursors to CD56dim 
cells. In particular, it has been demonstrated that appearance of 
CD56bright cells precedes that of CD56dim cells after HSCT (40) 
and that it is possible to induce differentiation of CD56bright into 
CD56dim NK cells in vitro in response to signaling via fibroblast 
growth factor receptor 1 (41). On the other hand, the model 
according to which CD56bright cells precede CD56dim cells during 
NK  cell development has been challenged by NK  cell lineage 
tracking experiments with genetic bar coding in macaques, which 
have suggested that these subsets may have distinct ontogeny (42).
In any case, the demonstration that composition of the 
peripheral NK  cell compartment varies with age indicates that 
appropriate age-matched controls should be used when analyzing 
NK cell phenotype in pathological conditions.
In particular, by performing an extensive phenotypic analysis, 
we have shown that NK  cells from patients with RAG/NHEJ 
defects comprise a higher proportion of CD56bright CD16−/int 
NKG2A+++ cells, and a reduced percentage of CD56dim CD16hi 
cells expressing CD57, KIRs, and CXCR1, than observed in age-
matched healthy controls. Altogether, these observations suggest 
that NK cells from patients with RAG/NHEJ defects have a more 
immature phenotype when compared to age-matched healthy 
controls, in spite of the fact that NK  cells from CID patients 
showed signs of progressive differentiation as compared to 
NK cells from patients with SCID/OS/AS. These data contrast 
with recent findings in Rag−/− mice, whose peripheral NK cell 
compartment is characterized by a predominance of cells express-
ing KLRG1, a marker of mature NK  cells (30). Furthermore, 
peripheral NK  cells from Rag−/− mice are largely CD62L−, 
indicating an in vivo activated phenotype (30). By contrast, we 
did not observe increased expression of CD69, an activation 
marker (43), in NK cells from patients with RAG/NHEJ defects, 
FigUre 9 | (a) Natural killer (NK) cells degranulation, expressed as percentage of CD107a+ cells, upon co-culture of peripheral blood mononuclear cells from 
patients with severe combined immune deficiency (SCID) and healthy infants with K562 target cells, in the absence (left and middle panels) or presence (right panel) 
of stimulation with exogenous interleukin-2 (IL-2). The middle panel shows degranulation of CD56bright (left) and CD56dim (right) NK cells from SCID patients and 
healthy infants in the absence of IL-2 stimulation. (B) Representative example (left) of perforin expression in resting NK cells from a patient with SCID due to RAG 
defect (red) and a healthy infant (blue), and mean fluorescent intensity (MFI) of perforin expression (right) in patients with SCID/OS/AS due to recombinase-activating 
gene (RAG)/non-homologous end-joining (NHEJ) defects and healthy infants. Bars represent mean ± SD values. *p < 0.05; **p < 0.01.
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including those with OS, a condition characterized by accumula-
tion of in vivo-activated autologous T cells. While the reasons for 
these discrepancies are not clear, murine and human NK cells 
differ substantially, also in regard to phenotypic markers that are 
differentially expressed during development.
By affecting the process of V(D)J recombination, mutations 
in RAG and NHEJ genes profoundly affect generation of T and 
B lymphocytes. Consistent with this, patients with RAG/NHEJ 
gene defects had a markedly reduced number of circulating 
B and T cells, with the exception of patients with OS, some of 
which had a normal or even increased number of oligoclonal and 
activated T cells, as typically observed in this disease. Previous 
studies in TCRβδ−/− and in μMT−/− mice had demonstrated that 
lack of T and B cells have opposite effects on the count of splenic 
NK cells. In particular, T cell deficiency is associated with a two-
fold to threefold increase, and B cell deficiency with a twofold 
to threefold decrease of NK cell count as compared to C57BL/6 
wild-type mice (44). The patients with RAG and NHEJ defects 
included in this study had either normal or increased count 
of circulating NK cells. In order to rule out the possibility that 
their abnormalities of NK cell phenotype could be secondary to 
T and B cell lymphopenia, we have included in this study patients 
with XLA (who lack circulating B  cells) and with other forms 
of TCD, including seven patients with SCID not due to RAG/
NHEJ defects. Even when compared to these two control groups, 
patients with SCID due to RAG/NHEJ gene defects had a mark-
edly increased proportion of CD56bright CD16− CD57− NKG2A+++ 
cells. Similar differences were also observed also when comparing 
NK cells from patients with OS/AS and those with TCD or XLA, 
with an increased percentage of CD56bright CD16− CD57− cells 
in the former. Altogether, these data indicate that the increased 
representation of immature cells within the peripheral NK cell 
compartment of patients with RAG/NHEJ defects is not second-
ary to T and B cell lymphopenia.
Because of their severe T  cell immunodeficiency, patients 
with RAG/NHEJ defects are highly prone to viral infections, 
including CMV. LIR-1 is a member of the immunoglobulin 
superfamily which has been shown to bind the human CMV 
MHC class I homolog UL-18 protein (45). NKG2A and NKG2C 
represent inhibitory and activating forms of CD94, recognizing 
non-classical HLA-E molecules (46). CMV infection can drive 
expansion of KIR+ and/or LIR-1+, NKG2A− NKG2C+ NK cells 
(34). Furthermore, rapid differentiation of CD56dim NKG2C+ 
NKG2A− CD57+ cells has been observed after CMV reactiva-
tion in recipients of HSCT (47). It has been shown that upon 
transfer from CMV-seropositive donors into seropositive HSCT 
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recipients, NKG2C+ cells undergo expansion and produce high 
amounts of IFN-γ as compared to NKG2C+ cells transfused into 
CMV-seronegative recipients, implying that NKG2C+ cells may 
represent “memory” NK cells capable of a prompt response upon 
re-exposure to CMV (48). Finally, rapid expansion of NKG2C+ 
NK cells has been reported in infants acquiring perinatal CMV 
infection (39). Although several of the patients included in this 
study had a history of CMV infection, no particular expansion 
of NKG2C+ and/or LIR-1+ cells was observed. Monocytes are 
apparently required to allow expansion of adaptive/memory-like 
NK  cells (49). Lack of expansion of NKG2C+ cells in CMV-
infected, RAG-/NHEJ mutated SCID patients may reflect a 
requirement also for T cell help in this process and may further 
contribute to poor control of CMV infection in these patients.
CD56bright and CD56dim NK cells differ in their immunomodu-
latory and effector function. In particular, CD56bright cells are 
potent producers of IFN-γ, but have lower content of perforin and 
display reduced cytotoxic activity as compared to CD56dim cells. 
Analysis of IFN-γ production by CD56bright and CD56dim NK cells 
from patients and controls confirmed that CD56bright cells were 
more potent producers of IFN-γ, irrespective of the underlying 
diagnosis. However, the proportion of CD56dim NK cells produc-
ing IFN-γ was lower in patients with SCID/OS/AS due to RAG/
NHEJ defects than in healthy infants or in patients with other 
forms of TCD, and a similar trend was observed for CD56dim cells 
from CID patients. These results suggest that RAG/NHEJ defects 
are associated with abnormalities of NK cells that are not restricted 
to their phenotype, but may also involve NK cell function. In this 
regard, it is particularly significant that NK cells from the patients 
displayed enhanced degranulation in the absence of previous 
stimulation with IL-2, and that CD56bright cells from patients with 
SCID/OS/AS had a higher content of perforin than CD56bright cells 
from healthy infants. Although we did not perform a chromium 
release assay to investigate NK cytolytic function, these data 
suggest that RAG/NHEJ defects are associated with enhanced 
effector function, similarly to what was previously reported for 
Rag−/− mice (30).
Expression of RAG may initiate prior to T and B cell differ-
entiation, as indicated by the presence of incomplete rearrange-
ments at the immunoglobulin heavy chain or T cell receptor loci 
in a minority of murine and human NK cells (29, 50). It has been 
suggested that introduction of DNA double strand breaks in 
lymphoid progenitor cells would facilitate selection of cells with 
more efficient DNA repair machinery (30). In the absence of this 
mechanism, NK  cells from Rag-deficient animals and humans 
would have reduced cellular fitness. Our data indicate that indeed 
patients with mutations in RAG or in NHEJ genes share similar 
abnormalities of NK cell phenotype and function. While it is not 
known whether the immunoglobulin and T  cell receptor loci 
represent the only sites in the genome that are targeted by RAG 
during early stages of lymphoid development, it is interesting to 
note that selective loss of CD56dim cells, with relative preserva-
tion of the CD56bright NK cell compartment, has been reported in 
patients with mutations of MCM4 and POLE2 genes, all of which 
control DNA replication (51–53).
In conclusion, we have identified for the first time abnormali-
ties of NK cell phenotype and function in patients with mutations 
in RAG and in genes involved in NHEJ. These abnormalities are 
more pronounced in patients with severe mutations associated 
with a more severe clinical and immunological phenotype, and 
are not secondary to T and B cell lymphopenia. Demonstration of 
enhanced degranulation activity and higher amount of perforin 
in NK cells from patients with SCID due to RAG/NHEJ defects 
suggests that inclusion of serotherapy targeting NK cells in the 
HSCT conditioning regimen may help reduce the risk of graft 
rejection that has been reported in these diseases.
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